Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date have led to a Non-Data Safety Monitoring Board reviewing the trial unanimously recommending it continue. Not only have there been no serious adverse events, but all…

ByNick SundichNovember 6, 2024

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months. Imugene (ASX:IMU) share price chart, log scale (Source: TradingView) Even though it has assets that have passed Phase 2 trials, it has never gotten to Phase 3. Yet it has $93.1m…

ByNick SundichOctober 22, 2024

Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2

Island Pharmaceuticals (ASX:ILA) is one of the few (if not the only) ASX-listed Biotechs that is focused on mosquito diseases, primarily Dengue fever. Mosquito diseases, such as Dengue, are expensive to treat and are expected to proliferate due to climate change and the consequential boom in the mosquito population. But maybe Island Pharmaceuticals can help. Introduction…

ByNick SundichOctober 15, 2024

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why. For many companies, the golden market has been the USA, given its population and stringent regulator the Food and Drug Administration (FDA). If a company can commercialise a drug in the USA, it can succeed…

ByNick SundichOctober 15, 2024

3 US Stocks to Watch if the Democrats Win the 2025 Election

With the 2025 U.S. presidential election on the horizon, investors are keeping a close eye on how a Democratic win could impact the markets. Renewable energy, healthcare, as well as infrastructure are the usual focus areas of Democratic policies and all are vying for growth if the party wins the White House. In this article,…

ByUjjwal MaheshwariOctober 5, 2024

Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!

The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced to the strategic functioning of the share markets. But just because you're not using actual money, it doesn't mean you should take it seriously. This blog will identify the best practices to assist you in…

ByUjjwal MaheshwariOctober 1, 2024

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

For Australian investors and traders, staying informed about stock market news is essential for making smart decisions. With a range of websites now providing real-time data, expert analysis, and market insights, investors have the tools to navigate the ever-changing world of stocks. This article highlights five of the most reliable websites offering stock market news…

ByUjjwal MaheshwariSeptember 25, 2024

Should you invest in aged care stocks? Here are 4 reasons to consider them, and 4 reasons to avoid them

Should you invest in aged care stocks? There are plenty of things to like about this sector, including government funding, resilience to tough economic times and the growth in demand that will come as the Baby Boomers age. But it is not all. Should you invest in aged care stocks? The Yes case 1. Ageing population…

ByNick SundichSeptember 17, 2024

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

For ASX biotechs wishing to commercialise drugs in Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme is the next best thing to regulatory approval. Therapeutic goods need to be included on the Australian Register of Therapeutic Goods (ARTG), prior to being sold, imported or exported from Australia. However, the Special Access Scheme provides a way…

ByNick SundichSeptember 16, 2024

The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!

The Pitt Street Research Life Sciences Conference is happening on September 19, 2024! The Life Sciences sector in Australia and New Zealand continues to mature in 2024. In spite of a difficult market for small-cap stocks on the ASX, companies are making progress in the clinic and management teams are building on their learnings…

ByNick SundichSeptember 13, 2024

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

3 US Stocks to Watch if the Democrats Win the 2025 Election

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

Should you invest in aged care stocks? Here are 4 reasons to consider them, and 4 reasons to avoid them

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here